The central contribution of IL-23/IL-17 axis in both PsA and psoriasis is confirmed by the efficacy of biologics neutralizing IL-17 or IL-23/IL-12 (187) as well as the effectiveness of TNF-α inhibition dependent on down-regulation of IL-17 pathway genes (188–190). The gene discussed is IL37; the disease is psoriasis.